Aarti Drugs (AARTIDRUGS.NS) Earnings Analysis

Aarti Drugs (AARTIDRUGS.NS) next reports earnings on 2026-07-23, consensus EPS 5.4 INR. Last quarter (2026-05-15) it beat with EPS 6.05 INR vs 5 INR est (+21%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E 19.16.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AARTIDRUGS.NS next report earnings?

Next earnings date2026-07-23
Consensus EPS estimate5.4 INR
Revenue estimate6.66B

AARTIDRUGS.NS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-156.05 INR5 INR+21%Beat
2026-02-034.4 INR4.9 INR-10.2%Miss
2025-10-224.9 INR4.9 INR0%Beat
2025-07-185.9 INR4.9 INR+20.4%Beat
2025-01-294.1 INR3.7 INR+10.8%Beat
2024-10-243.9 INR3.9 INR0%Beat
2024-07-263.6 INR4.1 INR-12.2%Miss

Beat rate: 5/7 (71%) over reported quarters with consensus data.

AARTIDRUGS.NS valuation and analyst view

Trailing P/E19.16
Trailing EPS21.368 INR
Price / book2.41
Dividend yield0.49%
Market cap37.60B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Aarti Drugs (AARTIDRUGS.NS)'s next earnings date?

Aarti Drugs is next scheduled to report on 2026-07-23, with a consensus EPS estimate of 5.4 INR and revenue estimate of 6.66B.

Did AARTIDRUGS.NS beat earnings last quarter?

In its 2026-05-15 report, AARTIDRUGS.NS posted EPS of 6.05 INR versus a 5 INR estimate — a beat of 21%.

What is AARTIDRUGS.NS's earnings track record?

Over the last 7 reported quarters with consensus data, AARTIDRUGS.NS beat estimates 5 times (71%).

What is AARTIDRUGS.NS's current P/E ratio and EPS?

AARTIDRUGS.NS trades at a trailing P/E of 19.16 on trailing EPS of 21.367911601240916 INR.

What do analysts rate AARTIDRUGS.NS?

AARTIDRUGS.NS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.